The 2021 treatment algorithm for FLT3-mutated AML

Naval Daver, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview the 2021 treatment algorithm for Fms related receptor tyrosine kinase 3 (FLT3) mutated acute myeloid leukemia (AML). Current guidelines recommend testing for the FLT3 mutation at diagnosis, but there is mounting evidence that suggests that the FLT3 mutation can arise at any time, suggesting that it should be tested for repetitively, and at each relapse. Dr Daver additionally discusses the addition of second generation FLT3 inhibitors such as midostaurin to cladribine or fludarabine with high-dose cytarabine and idarubicin paired with early transplant to achieve improved outcomes. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.